Generate Biomedicines is trading 5.26% higher at $12.90 in pre-market on October 14 after its October 13 Zealand Pharma partnership to develop AI-designed protein therapeutics for obesity and other metabolic diseases.
- Terms include $30 million upfront, up to $35 million in early milestones and potential milestone payments approaching $1.2 billion.
- Reuters and Bloomberg reported the deal. Shares closed the prior session at $12.26 after an 11.45% decline; broader market indicators were mixed and offer a less direct explanation for the move.